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Figure 1C. Platelet Count. TBI (7.25Gy).
Figure 1D. Platelet. TBI (7.0 Gy) +/- anti-CD41 Ab (5 mg).
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LRD were analyzed using Cox regression models.
Results: HMPV was detected in 118 HCT recipients. Most
cases were identiﬁed between December and May. The me-
dian time to HMPV detection after HCT was 278.5 days
(range -5e2773). Among 118 patients, 88 and 30 had URI
alone and LRD, respectively. The median viral load in nasal
wash samples was 1.2x106copies/ml (range, 3.3x10-1.6x109).
Among 30 patients with LRD, 17 patients progressed from
URI to LRD after a median of 7 days (range, 2e63). The
probability of 40-day progression to LRD was 16%. Progres-
sion rates decreased with increasing time between HCT and
HMPV infection (Figure 1; 0-30 vs. >365 days, p¼0.009, 31-
365 vs. >365 days, p¼0.09). Multivariate Cox analysis
showed that only steroid use 1mg/kg within 2 weeks
prior to diagnosis was signiﬁcantly associated with
progression to LRD (adjusted HR 4.1, p¼0.04), although
earlier detection of HMPV after HCT (day 0-30, HR 3.5,
p¼0.01), low lymphocyte count (<100 cells/mm3, HR 4.0,
p¼0.008), and low monocyte count (<100 cells/mm3, HR
2.9, p¼0.04) were also important factors in the univariate
analyses. Viral load in nasal wash samples at diagnosis was
not a predictor for progression to LRD.
Conclusions: HMPV infections in HCT recipients occurred
primarily in the winter and spring. The progression rate from
URI to LRD approached 40% in patients who acquired HMPV
infection within 30 days after HCT, likely related to low cell
counts, while later acquisitionwas associated with lower risk
of progression. The most important risk factor of progression
to LRD was steroid use of 1mg/kg prior to URI. Further
studies are needed to deﬁne the role of viral load in the
pathogenesis of progressive disease.114
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Figure 1B. Survival. TBI(7 0 Gy)+/-anti-CD 41Ab(5 mg).
Figure 1E. On necropsy intestines were found to be ﬁlled with black, mela-
notic stool. Guaiac positive CBC from moribund mice revealed hemoglobin n
the 3-5 g/dL range consistent with fatal gastrointestinal hemorrhage.
Figure 1F. Bleeding Time as a Function of Platelet Count, Saphenous Vein
Bleeding Model.
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Introduction: Thrombocytopenia (TCP) may cause severe
and life-threatening bleeding. While TCP-related bleeding
may be prevented by platelet transfusions, transfusions are
associated with signiﬁcant costs and complications. There is
an urgent need for a synthetic alternative.
Methods and Results: We evaluated the ability of ﬁbrin-
ogen-coated nanospheres (FCN) to prevent TCP-related
bleeding. FCN are made of human albumin polymerized into
a 400 nm sphere and coatedwith ﬁbrinogen.We hypothesize
that FCN bind to platelets through ﬁbrinogen-GPIIb/IIIa in-
teractions, contributing to hemostasis in the setting of TCP.
We used twomurinemodels to test the hemostatic effects
of FCN: in the ﬁrst, BALB/c mice received 7.25 Gy total body
irradiation (TBI) on day 0. This dose was selected after
titration to induce fatal hemorrhage in 2/3 of animals. In the
second model, to more selectively look at the effects of TCP,
we used a lower dose of radiation (7.0 Gy TBI), but this was
combined with an anti-platelet antibody (anti-CD41 5 mcg
ip) on Days 0, 5, 10 to induce severe TCP. FCN 8 mg/kg iv or
saline (control) were injected Days 1, 5, and 10 in both
models to correspond with the period of TCP nadir.Figure 2. FCN were labeled with Alexa Fluor 488 (green); platelets with anti-CD31
collagen (col) (2D, 2E, 2F), a platelet agonist. In the absence of collagen, FCN forms dis
and green particles on overlay (2C). In the presence of collagen, FCN clumps on green
(2F). Mixing control spheres (CS, albumin spheres without ﬁbrinogen, also labeled wi
suggesting that the ﬁbrinogen coating is necessary for nanosphere-platelet interactioFCN signiﬁcantly improved survival compared to saline
control in both models (Fig. 1A, 1B; both p<0.001). All deaths
were due to gastrointestinal or intracranial bleeding, sug-
gesting FCN improved survival by improving hemostasis. In
particular, addition of anti-platelet antibody to 7.0 Gy TBI
signiﬁcantly increased mortality (Fig. 1B, blue) compared to
just 7.0 Gy TBI (Fig. 1B, green), suggesting that deaths were
primarily due to severe TCP. As FCN did not improve platelet
numbers compared to control (Fig. 1C, 1D), we inferred
that FCN improved hemostasis by enhancing function.
Additionally, in a saphenous vein bleeding model of anti-
body-induced TCP, FCN shortened bleeding times in a
TCP-dependent manner (Fig. 1F). There were no clinical
signs of thrombosis or laboratory ﬁndings of disseminated
intravascular coagulation after FCN. Also of support of safety,
ﬂuorescence microscopy suggests that FCN bind to platelets
only upon platelet activation with collagen (Fig 2), limiting
activity to areas of endothelial damage.
Interestingly, no differences in platelet aggregation or clot
strength were detectable on light aggregometry (PAP-8E),
impedance aggregometry (Multiplate), or thromboelastog-
raphy (TEG, ROTEM). Nor were differences seen in ﬁbrin
formation (Fig 3A). However, FCN signiﬁcantly inhibited clot
lysis in a dose-dependent manner compared to ﬁbrinogen or
control spheres (albumin, no ﬁbrinogen) (Fig 3B).
Conclusion: FCN may prevent TCP-related bleeding by
interacting with platelets and inhibiting clot lysis. FCN may
reduce the need for platelet transfusions.PE antibody (red), and both mixed in the absence (2A, 2B, 2C) or presence of
crete particles on the green channel (2A), platelets on red (2B), and discrete red
(2D) correspond to platelet clumps on red (2E) and yellow clumps on overlay
th Alexa Fluor 488) with platelets failed to form yellow clumps on overlay (21),
ns.
Figure 3. To evaluate ﬁbrin formation, ﬁbrinogen is combined with thrombin and the optical density (absorbance) of the resultant clot is measured. Addition of FCH
at various doses (1:10, 1:1, 10:1) did not change clot density, while addition of ﬁbrinogen increased clot density in a dose-dependent manner (Fig 3A). However,
addition of FCN did have a signiﬁcant inhibitory effect on clot lysis (Fig 3B): in this model, plasm in was added to the combination of ﬁbrinogen and thrombin. The
addition of pi asm in lysesthe ﬁbrin as it is formed (CTL vs. CTL-HP (control no plasmin)); this activity is inhibited by FCN in a dose-dependent manner and is superior
to ﬁbrinogen alone or control spheres (CS, albumin spheres without ﬁbrinogen). All groups n¼8.
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